Buy GlaxoSmithKline Pharmaceuticals; target of Rs 2900: ICICI Securities
ICICI Securities upgraded GlaxoSmithKline Pharmaceuticals (GSK) to BUY with a target price of INR 2,900. GSK reported 20.8% revenue growth in Q2FY27, with innovative brands contributing 7% of sales. The company expects double-digit revenue growth and a 34% EBITDA margin for FY27, according to the report.
How this was made
The 30-second read
Why it matters
The earnings beat and upgraded rating suggest a near‑term rally, but execution risk remains on upcoming product launches.
Market read
First‑time upgrade on fresh earnings data provides a clear trading signal for GSK.
What to watch
Potential supply‑chain risks at CMO partners and GST policy changes could affect future performance.
Background
GlaxoSmithKline Pharmaceuticals reported a 20.8% YoY revenue increase in Q2FY27, driven by innovative brands and oncology launches.
Ticker impact
ICICI Securities upgraded GlaxoSmithKline Pharmaceuticals to BUY with a target of INR 2,900 after reporting Q2FY27 results.
likely upward pressure as investors price in the buy rating and strong margin guidance
Analyst upgrade with specific target and margin outlook is fresh, material information for a large cap pharma.
Market effects
Boosts sentiment for the broader pharma sector as earnings guidance improves.
Supports Indian market sentiment given the INR‑denominated target.
May influence global pharma peers as analysts reassess growth prospects.
Counterpoint
Some investors may view the upgrade as premature given macro‑economic headwinds.
Key entities
- CompanyGlaxoSmithKline Pharmaceuticals
UK‑based pharma firm with US ADR GSK.
- Research FirmICICI Securities
Issued the BUY upgrade and target price.
